TR200101882T2 - Tiazolidindion türevlerinin erken doğum halinde uterus kasılmalarını veya laktasyonu önlemek için kullanımı - Google Patents

Tiazolidindion türevlerinin erken doğum halinde uterus kasılmalarını veya laktasyonu önlemek için kullanımı

Info

Publication number
TR200101882T2
TR200101882T2 TR2001/01882T TR200101882T TR200101882T2 TR 200101882 T2 TR200101882 T2 TR 200101882T2 TR 2001/01882 T TR2001/01882 T TR 2001/01882T TR 200101882 T TR200101882 T TR 200101882T TR 200101882 T2 TR200101882 T2 TR 200101882T2
Authority
TR
Turkey
Prior art keywords
preterm labor
lactation
uterine contractions
thiazolidinedione
thiazolidinedione derivatives
Prior art date
Application number
TR2001/01882T
Other languages
English (en)
Inventor
John A. Copland, Iii
L. Ives Kirk
Soloff Melvyn
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of TR200101882T2 publication Critical patent/TR200101882T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Bu bulus, troglizaton gibi bir tiazolidindion bilesigi veya tiazolidindion benzeri bilesikler kullanmak suretiyle, oksitosin araciligi ile meydana gelen bir etkinin önlenmesi veya azaltilmasi ile ilgilidir. Burada bu bilesiklerin yalniz olarak veya bir tokolitik madde gibi en az bir baska madde ile kombinasyon halinde kullanimi tarif edilmistir. Bu kullanim, örnegin uterus kasilmalarinin baslatilmasi, prostaglandin tahliyesi ve süt salgilanmasi gibi oksitosin araciligi ile olusan etkilerin tedavi edilmesi için yeni bir terapötik yöntem saglar. Böylece, erken dogum sancilari ve sezeryan ameliyati ile dogum öncesinde dogum sancilari gibi durumlar, bu yöntemler vasitasiyla tedavi edilebilir.
TR2001/01882T 1998-10-29 1999-10-29 Tiazolidindion türevlerinin erken doğum halinde uterus kasılmalarını veya laktasyonu önlemek için kullanımı TR200101882T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10613398P 1998-10-29 1998-10-29

Publications (1)

Publication Number Publication Date
TR200101882T2 true TR200101882T2 (tr) 2001-12-21

Family

ID=22309672

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01882T TR200101882T2 (tr) 1998-10-29 1999-10-29 Tiazolidindion türevlerinin erken doğum halinde uterus kasılmalarını veya laktasyonu önlemek için kullanımı

Country Status (19)

Country Link
US (1) US7528133B1 (tr)
EP (1) EP1126844A1 (tr)
JP (1) JP2002528500A (tr)
KR (1) KR20010089381A (tr)
CN (1) CN1328456A (tr)
AU (1) AU1330800A (tr)
BR (1) BR9915820A (tr)
CA (1) CA2348910A1 (tr)
CZ (1) CZ20011524A3 (tr)
HK (1) HK1041213A1 (tr)
HU (1) HUP0104900A3 (tr)
ID (1) ID29352A (tr)
IL (1) IL142841A0 (tr)
MX (1) MXPA01004257A (tr)
NO (1) NO20012090L (tr)
PL (1) PL347508A1 (tr)
TR (1) TR200101882T2 (tr)
WO (1) WO2000025781A1 (tr)
ZA (1) ZA200103999B (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062563A2 (en) * 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
EP3382391A1 (en) 2012-10-24 2018-10-03 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
BR112018013597A2 (pt) * 2016-01-04 2019-01-08 ObsEva S.A. composição farmacêutica, método para tratar ou impedir o trabalho de parto prematuro, método para impedir o trabalho de parto antes do parto cesariana, método para tratar ou impedir a dismenorreia e kit
MX2020002788A (es) 2017-09-13 2020-09-14 Progenity Inc Biomarcadores de preeclampsia y sistemas y metodos relacionados.
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
CN1196730A (zh) 1996-06-19 1998-10-21 雷迪博士研究基金会 具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Also Published As

Publication number Publication date
HUP0104900A3 (en) 2003-02-28
JP2002528500A (ja) 2002-09-03
HUP0104900A2 (hu) 2002-04-29
MXPA01004257A (es) 2002-06-21
WO2000025781A1 (en) 2000-05-11
ZA200103999B (en) 2002-08-16
AU1330800A (en) 2000-05-22
CZ20011524A3 (cs) 2002-01-16
KR20010089381A (ko) 2001-10-06
IL142841A0 (en) 2002-03-10
CN1328456A (zh) 2001-12-26
US7528133B1 (en) 2009-05-05
PL347508A1 (en) 2002-04-08
BR9915820A (pt) 2001-10-30
CA2348910A1 (en) 2000-05-11
HK1041213A1 (zh) 2002-07-05
NO20012090L (no) 2001-06-27
EP1126844A1 (en) 2001-08-29
NO20012090D0 (no) 2001-04-27
ID29352A (id) 2001-08-23

Similar Documents

Publication Publication Date Title
ZA88798B (en) Dental anti-plaque and anti-caries agent
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
CY1110282T1 (el) Ενωσεις για την αγωγη της απωλειας βαρους
DE69022722T2 (de) Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
GB229644A (en) A method of producing a substance adapted to tampon wounds
ATE190840T1 (de) Zusammensetzung zur behandlung der parkinson- krankheit
TR200101882T2 (tr) Tiazolidindion türevlerinin erken doğum halinde uterus kasılmalarını veya laktasyonu önlemek için kullanımı
ATE68686T1 (de) System zum freigeben von stoffen in der vagina.
ATE173297T1 (de) Verfahren zur erkennung und behandlung anomaler zellen
DE69721462D1 (de) Verfahren zur Förderung von Ovulation und Geburt bei Säugetieren
Hunskaar A case of ecthyma contagiosum (human orf) treated with idoxuridine
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
CN204351939U (zh) 一种辅助孕妇生产专用装置
DE60021111D1 (de) Verwendung von fibrinolytischen metallproteinasen zur behandlung von blutgerinseln
McFarland et al. Concentration of ACTH in cavernous sinus and peripheral blood collected from unanesthetized sheep.
Landesman et al. Uterine relaxant properties of bradykinin in vitro
Patel et al. Effect of hormonal and herbal therapy at calving on postpartum estrus and fertility response and serum hormonal profile in crossbred cows
Bontekoe et al. On the influence of orciprenaline on uterine motility and on plasma levels of estradiol-17β in pregnant and parturient sheep
SU628893A1 (ru) Способ сн ти пов зок с раны
Qvist Operations for Duodenal Ulcer
Cole Tumours of the Oesophagus
Turner Shock and first aid in the dog and cat
JPS568324A (en) Infectious disease remedy for external and ophthalmologic application
Callahan The bacteriology of septic abortion.
EA202191119A1 (ru) Способы лечения миелодиспластического синдрома